AML-FLT3

Now enrolling patients for a phase 2/3 clinical study for the treatment of AML patients with FLT3 mutations who are not eligible for intensive induction therapy.

The study will evaluate treatments with:
ASP2215 (Gilteritinib)
ASP2215 Plus Azacitidine
Azacitidine Alone

Gilteritinib has demonstrated inhibitory activity against FLT3 internal tandem duplication (ITD), as well as tyrosine kinase domain (TKD), two common types of FLT3 mutations that are seen in 1/3 of patients with Acute Myeloid Leukemia.

CLL

Now enrolling patients for the InformCLL Registry. The purpose of the InformCLL Registry is to characterize and describe treatment patterns for those initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL /SLL therapies/regimens.

This study also evaluates association of treatment patterns with patient characteristics, healthcare resource utilization and patient reported Health related Quality of Life (HRQoL).

Hodgkin Lymphoma

Now Enrolling a Phase II Study of Oral HDAC-inhibitor Abexinostat in Patients with Relapsed or Refractory Follicular Lymphoma

Inhibition of histone deacytelases (HDAC) has emerged as a promising therapeutic strategy in hematologic malignancies. Abexinostat is a novel, oral, broad-spectrum phenyl hydroxamic acid–based HDAC inhibitor.

This Phase II study is now enrolling patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat tablets in a "one week on, one week off" schedule.

Mantle Cell Lymphoma

Now enrolling patients in a Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Bendamustine and Rituximab (BR) Alone Versus in Combination with Acalabrutinib (ACP-196) in patients with Previously Untreated Mantle Cell Lymphoma.

Leukemia and Lymphomas CLL/SLL and MCL

Now enrolling patients for a Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab (UC-961), and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies

You are being asked to take part in a research study because you have chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or mantle cell lymphoma (MCL). This research study is evaluating an investigational drug, called cirmtuzumab, in combination with a standard drug, called ibrutinib (Imbruvica®), as a possible treatment for patients with CLL/SLL or MCL.

CLL/SLL Non-Hodgkin's Lymphoma

Now enrolling patients in A Phase 1 a/b Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with CLL/SLL or Non-Hodgkin's Lymphomas

CG-806 is a small molecule kinase inhibitor with the potential to treat patients with broad range of B cell malignancies, including those that are sensitive to and those resistant, refractory, or intolerant to standard therapies, as well as a breadth of patients with AML, including those resistant to current FLT3 inhibitors.

CG-806 is the first agent to potentially inhibit all known forms of both FLT3 and BTK enzymes and to inhibit key oncogenic compensatory pathways without inhibiting kinase generally known to induce toxicity.

Purpose of the study:

• To determine the dose of CG-806 given orally every 12 hours that maintains a biologically active plasma concentration over a period of 28 days.
• To establish the recommended Phase 2 dose (RP2D) of CG-806 for future clinical trials in patients with advanced CLL/SLL or NHL.
• To determine the PK profile of CG-806 when administered orally on an every 12 hour schedule.
• To assess the antitumor activity of CG-806 using imaging and biomarker evaluations.
• To determine the ability of CG-806 to alter the expression of pharmacodynamic biomarkers of drug effect.